Gene therapy inhaler for cystic fibrosis tested, but study stopped early
NCT ID NCT06515002
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tested a single dose of an inhaled gene therapy called BI 3720931 in adults with cystic fibrosis who cannot use standard CFTR modulator drugs. The goal was to see if it was safe and could improve lung function. The study was terminated early after enrolling only 5 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hôpital Gui de Chauliac
Montpellier, 34295, France
-
Osp. Pediatrico Bambin Gesù
Roma, 00165, Italy
-
Royal Brompton Hospital
London, SW3 6JY, United Kingdom
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
Conditions
Explore the condition pages connected to this study.